Huntington's Disease Therapeutics: Market Research Report

January 2015 | 122 pages | ID: HA96DDB8C18EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Huntington's Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as -

• Alnylam Pharmaceuticals, Inc.
• Auspex Pharmaceuticals, Inc.
• Intellect Neurosciences Incorporation
• Lundbeck A/S
• Prana Biotechnology Limited

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

A Prelude
Current HD Treatment
Huntington’s Disease – Quick Facts
Market Opportunity
Huntington’s Disease Prevalence in Major Region/Countries
Competition in the Global HD Therapeutics Market is Non-existent
Effectiveness of Current HD Management Strategies
HD Treatment and Drugs: Brief Description of Disorder, Medication and Side-Effects
Alternative Treatment Approaches for Huntington’s Disease
Alternate Approaches and Therapies
Off-Label Prescriptions
Select Off-Label Drugs Prescribed for Huntington’s Disease: Drug Name & Manufacturer; Treatment Class; and Primary Indication
mHtt Aggregates in HD—Molecular Pathogenesis

2. HD THERAPEUTICS MARKET TRENDS

Therapeutics Focus on Reduction of mHtt Expression
Companies Boost R&D Spending for HD Therapeutics
Improved Diagnostics Fueling Interest of Companies in HD Research
Support Organizations Play an Instrumental Role in HD Research and Awareness
Public-Private Partnerships: A Shot in the Arm
HD Research Attracts 'Big Pharma' Investment
Pre-Symptomatic Patients to Expand Market Base
HDSA Pushes for Improvement in Medicare Funding for Huntington’s Disease
GINA for Reducing Discrimination Faced by People with HD

3. HUNTINGTON’S DISEASE PIPELINE ANALYSIS

A Quick Primer
Drug Development Pipeline Reveals a Promising Picture
Select Drugs and Supplements in HD Research Pipeline (2014): Drug Name, Manufacturer, Mode of Action and Current Status
An Overview of Select Drugs in Late-Stage Clinical Trials

SD-809

RP103 (Procysbi)

PBT2

Huntexil (Pridopidine)
Other Novel Approaches for HD Treatment
Cellular Delivery of Neurotropic Agents
Cogane

COPREXA

Histone Deacetylases (HDAC)
Melatonin, Coenzyme Q-Free Radical Scavengers
RNAi - RNA Interference

4. RESEARCH BREAKTHROUGHS IN HD ARENA

Triglyceride Oil ‘Triheptanoin’ Shows Promise for HD Therapeutics
Reducing mTORC1 Activation through Drug/Diet May be Helpful
Better Understanding of Early Neuronal Changes Lead to Targeted Drug Development
Lund University Researchers Successfully Map Functionality of Hypothalamus in HD
MIB, University of Lisbon and University of Leicester Demonstrate Latest Findings on KMO Enzyme
Latest TRACK-HD Findings Demonstrate Early Identification of Huntington's Disease Progression in Patients
Researchers at BUSM, MGH, Columbia University and McLean BTRC Demonstrate Impact of Huntington's Disease on Human Brain
Researchers Demonstrate Significance of TFEB and PGC-1alpha Proteins in Prevention of HD
Florey Neuroscience Institutes Demonstrates Importance of Cognitive Stimulation in HD Patients
University of Wisconsin-Madison Waisman Center Demonstrates Stem Cell Therapy Potential for Treating HD
NUI Galway Announces Discovery of Experimental Drugs with Potential for Slowing Progress of HD
Lawrence Berkeley National Laboratory Designs Compound for Suppressing HD Symptoms
Development of HD Affected Human Brain Cells for Investigative Purposes
Device Implant in Brain Exhibits Therapeutic Potential for HD
Sangamo Biosciences on Path to Discover a Therapy for HD
Scientists at University of Rochester Medical Center Demonstrate Use of Coenzyme Q10 for Reduction of Oxidative Damage in HD Patients

5. AN OVERVIEW OF HUNTINGTON’S DISEASE

Introduction
Historical Background
Prognosis
Stages of HD
Symptoms and Signs
Physical Symptoms
Emotional Symptoms
Mental Symptoms
Genetics of Huntington's Disease
Inheritance
Mechanism
Functions of HTT
Effects of mHTT on Cells
Macroscopic Effects of mHTT
Diagnosis of HD
Clinical Diagnosis
Embryonic Diagnosis
Differential Diagnosis
Diagnostic Tests for Huntington's Disease
Confirmatory Diagnostic Test
Pre-symptomatic Diagnostic Test
Prenatal Diagnostic Test
Treatment Options
Nutrition and Eating
Social Activity
Speech Therapy
Physical Therapy
Occupational Therapy
Medication
Molecular Chaperones

6. RECENT INDUSTRY ACTIVITY

Auspex Reports Favorable Study Results of SD-809
Sangamo and Collaborators to Present ZFP Therapeutics Data
Sangamo Presents Positive Preclinical Data of ZFP Therapeutic
Sangamo BioSciences Acquires Ceregene
Prana Completes Reach2HD Trial
Teva Pharmaceuticals Forms Global R&D Collaboration for HD
KineMed, Isis and CHDI Foundation Collaborate for HD Therapeutics
CHDI Foundation Continues Collaboration with Medtronic
Roche Enters into Alliance with Isis Pharmaceuticals
Omeros Receives IND Approval for OMS824 for Huntington’s Disease
Teva Pharmaceutical Industries Signs Asset Transfer Agreement with NeuroSearch
uniQure and Benitec Biopharma Ink Cross-Licensing Agreement
Evotec and CHDI Foundation Extend Collaboration
Raptor Acquires Exclusive Rights to Cysteamine and Associated Compounds
GNS Healthcare Enters into Collaboration with CHDI Foundation
Lundbeck Collaborates with CHDI Foundation for HD Research
Horizon Discovery Collaborates with Institute of Neurology, London
Thomson Reuters and CHDI Foundation Enter into MetaMiner Partnership

7. FOCUS ON SELECT PLAYERS

Alnylam Pharmaceuticals, Inc. (US)
Auspex Pharmaceuticals, Inc. (US)
Intellect Neurosciences Incorporation (US)
Lundbeck A/S (Denmark)
Prana Biotechnology Limited (Australia)
Raptor Pharmaceuticals Corp. (US)
Sangamo Biosciences, Inc. (US)
Teva Pharmaceutical Industries Ltd (Israel)
Trophos SA (France)
Valeant Pharmaceuticals International, Inc. (Canada)
Vertex Pharmaceuticals Incorporated (US)

8. GLOBAL MARKET PERSPECTIVE

Table 1. World Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 2. World Historic Review for Huntington's Disease Therapeutics by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

Table 3. World 12-Year Perspective for Huntington’s Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
HDSA Brings about Improved Medicare Funding for Huntington’s Disease
GINA for Reducing Discrimination Faced by People with HD
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 4. The US Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 5. The US Historic Review for Huntington's Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2. EUROPE

Market Analysis

Table 6. European Recent Past, Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 7. European Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

Table 8. European 12-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, UK, Spain and Rest of Europe Markets for the Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

2A. FRANCE

A. Market Analysis
Trophos Sa – A Key Player
B. Market Analytics

Table 9. French Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 10. French Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2B. GERMANY

A. Market Analysis
Strategic Corporate Development
B. Market Analytics

Table 11. German Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 12. German Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2C. THE UNITED KINGDOM

A. Market Analysis
Outlook

Table 13. Juvenile HD Incidence Estimates in the UK(includes corresponding Graph/Chart)

Table 14. Juvenile HD Prevalence Estimates in the UK (2006-2010) (includes corresponding Graph/Chart)

Strategic Corporate Development
B. Market Analytics

Table 15. The UK Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 16. The UK Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2D. SPAIN

A. Market Analysis

KEY PLAYER - SOM BIOTECH

B. Market Analytics

Table 17. Spanish Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 18. Spanish Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

2E. REST OF EUROPE

A. Market Analysis
Strategic Corporate Development
B. Market Analytics

Table 19. Rest of Europe Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 20. Rest of Europe Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)

3. REST OF WORLD

A. Market Analysis
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 21. Rest of World Recent Past, Current & Future Analysis for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart)

Table 22: Rest of World Historic Review for Huntington’s Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart)III-28IV. COMPETITIVE LANDSCAPE
Total Companies Profiled:
The United States (13)
Canada (1)
Europe (8)
  France (1)
  Germany (1)
  The United Kingdom (2)
  Italy (1)
  Rest of Europe (3)
Asia-Pacific (Excluding Japan) (3)